Table 1.
Summary table of faecal calprotectin (FCP) measurements at Cambridge University Hospitals between October 2014 to July 2018.
Fig 1.
Distribution of faecal calprotectin (FCP) in the total cohort, including samples of healthy children and children with a gastrointestinal condition (e.g. IBD).
A Scatterplot of absolute FCP distribution of 2788 samples from 2788 children aged 0-16y. B Percentage of all patients (n = 2788) according to FCP range. 85% of all FCP values are < 250 μg/g, 90% are < 600 μg/g.
Table 2.
Summary of age-group-related comparison in FCP levels of the first cohort (n = 2788).
Fig 2.
A Proportion of patients with newly diagnosed IBD (red) and without IBD (green) according to their FCP of </≥ 50 μg/g, </≥ 250 μg/g and </≥ 600 μg/g. The difference between IBD diagnoses in patients with FCP < and ≥ 250 μg/g as well as in those with FCP < and ≥ 600 μg/g is statistically significant (p < 0.05). B Proportion of patients with/without IBD who were referred due to and not due to their elevated FCP (Ref. FCP and Ref. not FCP, respectively). C Proportion of patients with/without IBD and referred due to their FCP of 50–250 μg/g.
Table 3.
Summary of symptoms and blood test results of IBD patients with FCP < 600 μg/g (n = 9) and of IBD patients aged < 6y (n = 4).
Fig 3.
Flowchart providing a guideline on how to proceed with a child presenting with gastrointestinal symptoms in primary and secondary care.
IBD Inflammatory bowel disease; PR per rectum; TTG Tissue Transglutaminase; GI gastrointestinal; CRP C-reactive protein; ESR erythrocyte sedimentation rate; LFT’s liver function tests; GP General Practitioner.